IngredientesProanthocyanidins, also known as condensed tannins, are primarily found in fruits, nuts, bark, chocolate, wine, and some plant seeds and flowers. They belong to the broad class of flavonoids and are among the most structurally complex polyphenols found in the plant kingdom. Proanthocyanidins are ubiquitous and are among the most abundant natural phenol derivatives; they are mixtures of oligomers and polymers composed of flavan-3-ol repeating units linked through C4–C8 or C4–C6 bonds.
The general chemical structure of a polymeric proanthocyanidin consists of linear chains of 5,7,3′,4′-tetrahydroxy or 5,7,3′,5′-pentahydroxy flavonoid 3-ol units linked together through common C(4)–(6) and/or C(4)–C(8) bonds. The monomer unit (generally termed "leucoanthocyanidin") of the polymer chain may be based on either of two stereochemistries of the C-ring, at the 2 and/or 4 position designated cis (called epicatechins) or trans (called catechin).
The most common flavan-3-ols contained in proanthocyanidins are afzalechin, epiafzalechin, catechin, epicatechin, gallocatechin, and epigallocatechin. Proanthocyanidins consisting exclusively of catechin and epicatechin are called procyanidins, whereas those containing afzalechin and epiafzalechin or gallocatechin and epigallocatechin are the propelargonidins and prodelphinidins. Procyanidins are the most abundant in nature.
The flavan-3-ol units may also be doubly linked by an additional bond between C2–O7, referred to as the A-type linkage. B-type proanthocyanidins are linked by C4→C8 and/or C4→C6 bonds, while A-type proanthocyanidins contain an additional ether bond between C2→O7. This structural distinction carries significant biological relevance: A-type proanthocyanidins are particularly associated with cranberry and are responsible for its anti-adhesion properties in the urinary tract (discussed below).
According to the degree of polymerization, proanthocyanidins can be divided into oligomeric and highly polymeric proanthocyanidins, with the former considered to be safe and effective natural antioxidants that can effectively scavenge free radicals from the body and maintain homeostasis. Larger polymers of the flavonoid 3-ol units are predominant in most plants, and are found with average molecular weights above 2,000 daltons, containing 6 or more units.
In the scientific literature and supplement industry, proanthocyanidins are variously referred to as: condensed tannins, oligomeric proanthocyanidins (OPCs), oligomeric procyanidins, procyanidolic oligomers (PCOs), pycnogenols (a registered trade name for a specific pine bark extract), and leucoanthocyanins. The commercial designations Pycnogenol® (French maritime pine bark), Masquelier's OPCs (grape seed), and Oximacro® (cranberry) each refer to standardized extracts of specific proanthocyanidin preparations.
Proanthocyanidins are naturally occurring polyphenolic compounds abundant in many vegetables, plant skins (rind/bark), seeds, flowers, fruits, and nuts. They are commonly found in many plants and parts thereof, including apple skin, pine bark, cinnamon bark, grape seed, grape skin, cocoa seed, bilberries, cranberries, black currants, and chokeberry. The US Department of Agriculture maintains a database of botanical and food sources of proanthocyanidins.
Among the most commercially and clinically important sources are:
In nature, proanthocyanidins serve among other chemical and induced defense mechanisms against plant pathogens and predators.
Proanthocyanidins are commercially available in numerous forms:
The DMAC method is now endorsed as the method for quantifying A-type proanthocyanidins in high-grade cranberry extracts by a number of labs and associations including the United States Department of Agriculture (USDA), The Cranberry Institute, American Herbal Pharmacopoeia (AHP), European Food Safety Authority (EFSA), and Rutgers University. Controversial clinical results obtained with cranberry are often due to a lack of precise determination and authentication of the PAC-A content.
The formal scientific history of proanthocyanidins as isolable compounds dates to the mid-twentieth century, but plants containing them have served as medicines across many cultures for thousands of years.
The medicinal use of pine bark from different pine species can be traced back to Hippocrates, 400 B.C., and was applied in many parts of the world. Traditionally, pine bark has been used for its anti-inflammatory and wound healing effects. The pine tree belongs to the family Pinaceae and various parts, including cones, bark, and needles, have been used as an alternative medicine for numerous diseases. Among the parts of the pine tree, the bark has been used as a traditional remedy and nutritional supplement.
The process of concentrative extraction of OPCs from pine bark was established by Masquelier et al. in 1948. Masquelier's work, building on earlier observations about the nutritional importance of plant polyphenols, laid the groundwork for modern understanding and commercial use of proanthocyanidins as dietary supplements. He later developed grape seed extracts and coined the term "oligomeric procyanidins."
Cranberry products have been used widely for several decades to prevent urinary tract infections. In North American Indigenous traditions, cranberry was used medicinally by multiple tribes, including as a poultice and for urinary and kidney conditions. The first scientific hint that cranberry specifically inhibited urinary bacterial adhesion emerged in the late 20th century. A breakthrough was made in 1998 when Amy Howell et al. published a study in the New England Journal of Medicine identifying proanthocyanidins (PACs) as the compounds responsible for the process of bacterial anti-adhesion activity.
Grape products, including wine, have historically been used across Mediterranean and Middle Eastern cultures for wound healing, digestive conditions, and general health maintenance. Grape seed procyanidins have been identified as the molecular link between wine and its protective cardiovascular properties.
Hawthorn (Crataegus spp.), another rich source, has a long tradition of use in European and Chinese herbal medicine for heart and circulatory conditions. Crataegus has long been used as a folk medicine and is widely utilized in pharmaceutical preparations mainly because of its neuro- and cardiosedative actions and its low toxicity.
Flavan-3-ols are a subclass of flavonoids that includes the simple monomers (+)-catechin and its isomer (−)-epicatechin. Procyanidins are oligomers and polymers of flavan-3-ol through the interflavanoid linkage of 4→8 or 4→6 (B-type).
The major identified subclasses and individual compounds within proanthocyanidins include:
French maritime pine bark extract is a complex mixture of bioflavonoids, with oligomeric proanthocyanidins (OPCs) as the major constituents. OPCs are dimers or oligomers of catechin, epicatechin, and their gallic acid esters.
Proanthocyanidins effectively suppress oxidative stress through repairing DNA damage, preventing lipid peroxidation, and modulating signaling pathways (e.g., Nrf2, MAPKs, NF-κB pathways). As natural antioxidants, they are recognized as one of the most effective ways to remove free radicals from the human body.
Accumulation of prooxidants such as reactive oxygen species (ROS) exceeding cellular antioxidant capacity results in oxidative stress, which can damage macromolecules (DNA, lipids, and proteins), organelles (membranes and mitochondria), and whole tissues. Oxidative stress is implicated in the pathogenesis and exacerbation of many cardiovascular, neurodegenerative, dermatological, and metabolic diseases, both through direct molecular damage and secondary activation of stress-associated signaling pathways.
Numerous in vitro and in vivo studies have demonstrated myriad effects potentially beneficial to human health, such as antioxidation, anti-inflammation, immunomodulation, DNA repair, and antitumor activity. Anti-inflammatory mechanisms include inhibition of NF-κB, a master regulator of inflammatory gene expression, and inhibition of pro-inflammatory enzymes including 5-lipoxygenase (5-LOX) and cyclooxygenase-2 (COX-2).
Despite the antioxidant and anti-inflammatory properties of these flavonoids, one of the mechanisms by which proanthocyanidins exert their cardiovascular protection is improving lipid homeostasis. There is evidence to show that proanthocyanidins have multiple anti-atherosclerotic effects such as: regulation of lipoprotein disorders; lowering blood glucose and improving insulin resistance; anti-inflammatory effects; lowering blood pressure; vascular endothelial protection; inhibition of the proliferation of vascular smooth muscle cells; and antiplatelet aggregation.
Pycnogenol® (a pine bark procyanidin extract) antagonizes the vasoconstriction caused by epinephrine and norepinephrine by increasing the activity of endothelial nitric oxide synthase. Dilation of the small blood vessels has been observed in patients with cardiovascular disease, whereas in smokers, Pycnogenol® prevents smoking-induced platelet aggregation and reduces the concentration of thromboxane. The ability to inhibit angiotensin-converting enzyme is associated with a mild antihypertensive effect.
Cranberries contain proanthocyanidins, which inhibit the adherence of p-fimbriated Escherichia coli to the urothelial cells lining the bladder. Research suggests that A-type PACs inhibit the adherence of p-fimbriated Escherichia coli on uroepithelial cells of the bladder, preventing the adherence of bacteria to the mucosal surface of the urinary tract and thereby inhibiting bacterial proliferation. This mechanism is structurally specific: a key question remained as to why PACs from cranberry result in anti-adhesion activity when those from other berries do not have this action, with the answer lying in cranberry's unique enrichment in A-type linkages rather than B-type.
The molecular targets of proanthocyanidins in cancer include NF-κB, mitogen-activated protein kinases, PI3K/Akt, caspases, cytokines, angiogenesis-related factors, and cell cycle regulatory proteins. PACs have been shown to protect against oxidative stress and tobacco-induced DNA damage, and to exhibit selective cytotoxicity against some human cancers, including breast, lung, prostate, and gastric carcinomas. Evidence from in vitro and animal studies is extensive, but robust human clinical trial data specifically for cancer prevention or treatment are limited.
Proanthocyanidins can effectively inhibit caries through two pathways: (1) reducing caries-causing pathogens, such as Streptococcus mutans and their biofilms; and (2) promoting the mineralization of hydroxyapatite. Additionally, agents rich in proanthocyanidins can be effective in improving the function of dentin tissue, improving the mechanical stability and reducing collagen degradation.
A critical factor in understanding proanthocyanidin bioactivity is the relationship between molecular size and absorption. After ingestion, only a minor part of the monomeric flavan-3-ols (30% of (epi)catechins and 10% of (epi)gallocatechins) and traces of proanthocyanidins are absorbed in the upper gastrointestinal tract. Proanthocyanidins are polymers of high molecular weight, and therefore oligomers larger than trimers are unlikely to be absorbed in the small intestine in their native form.
After ingestion, a small amount of flavan-3-ol or proanthocyanidin oligomers are absorbed in the small intestine; the majority of them reach the colon. The majority of proanthocyanidins reach the colon intact and are degraded into phenylvalerolactones and phenolic acids by colon microbiota. These microbial metabolites may contribute to the health-promoting properties of proanthocyanidins in vivo.
Proanthocyanidin has low bioavailability, with 90% remaining unabsorbed from the intestines until metabolized by gut flora to the more bioavailable metabolites. When humans consumed a test drink containing PACs with a degree of polymerization ranging from 2 to 10, γ-valerolactones were mainly detected in the plasma, rejecting the notion that PACs are broken down into flavanols prior to their absorption.
Since the large molecular weight and degree of polymerization limit the bioavailability of proanthocyanidins, the major effective site of proanthocyanidins is proposed to be in the gut. Many studies have revealed the effects of proanthocyanidins from different sources on changing the composition of gut microbiota based on in vitro and in vivo models.
A reduction of microbial catabolism also occurs with A-type proanthocyanidins, since the additional ether linkage makes the interflavan linkage stiffer. The relationship between polyphenols, in particular flavan-3-ols, and gut microbiota is bidirectional: polyphenols can modulate the activity and composition of the gut microbiota, and the gut microbiota can catabolize them, influencing their bioavailability and bioefficacy.
Flavan-3-ol compounds used with methanol produce short-chain procyanidin dimers, trimers, or tetramers which are more absorbable. The smaller oligomers (dimers and trimers) have meaningfully greater absorption than higher-molecular-weight polymers, which is relevant to formulation design and dose standardization.
Proanthocyanidins are the most abundant polyphenols in human diets, and epidemiological studies strongly suggest that proanthocyanidins protect against cardiovascular diseases. One mechanism of cardiovascular protection is improving lipid homeostasis. Animal studies demonstrate that proanthocyanidins reduce the plasma levels of atherogenic apolipoprotein B-triglyceride-rich lipoproteins and LDL-cholesterol but increase antiatherogenic HDL-cholesterol. However, the results in humans are less clear.
Regarding blood pressure, a meta-analysis of 16 randomized controlled trials provides the most comprehensive human evidence to date. Pooling 16 clinical trials together identified significant reductions for systolic blood pressure (WMD = −6.077; 95% CI: −10.736 to −1.419; P = 0.011) and diastolic blood pressure (WMD = −2.803; 95% CI: −4.417 to −1.189; P = 0.001) after grape seed extract treatment relative to placebo. Furthermore, the beneficial impact of grape seed extract on blood pressure was more evident in clinical trials enrolling younger or obese subjects.
A randomized, double-blind, placebo-controlled study illustrates specific trial parameters: the study aimed to investigate the effects of grape seed proanthocyanidin extract (GSPE) on blood pressure and vascular endothelial function in middle-aged Japanese adults with prehypertension, and was conducted on 6 men and 24 women aged 40–64 years. Participants were randomized to receive tablets containing either low-dose (200 mg/day) or high-dose (400 mg/day) GSPE, or placebo, for 12 weeks. The mean systolic blood pressure in the high-dose group significantly decreased by 13 mmHg after 12 weeks (P = 0.028), although flow-mediated dilation did not change.
Despite evidence showing multiple anti-atherosclerotic mechanisms — including lipoprotein regulation, anti-inflammatory effects, blood pressure lowering, vascular endothelial protection, inhibition of smooth muscle cell proliferation, and antiplatelet aggregation — most research has been conducted in animals or in vitro experiments. The 2023 review in carotid atherosclerosis concluded that while the mechanistic data are compelling, large-scale, well-designed human trials are still needed.
Regarding venous health, in 39 randomized double-blind, placebo-controlled human clinical trials including 2,009 subjects, Pycnogenol® French maritime pine bark extract supplementation for two weeks to six months has been shown to beneficially affect cardiovascular health and chronic venous insufficiency, among other areas. Evidence characterization: moderate (multiple RCTs for blood pressure lowering, particularly with grape seed extract); the effect size is modest and heterogeneity between trials is notable.
Cranberry-derived bioactive compounds, particularly proanthocyanidins, have emerged as a promising non-antibiotic strategy for UTI prevention. The mechanism is anti-adhesion rather than antimicrobial. Cranberry metabolites, particularly A-type PACs, flavonoids, and phenolic acids, inhibit Escherichia coli adhesion to urothelial cells, reducing UTI recurrence.
In terms of dose-related clinical evidence, a meta-analysis specifically examining PAC content and UTI outcomes found that ten RCTs matching requirements were included. The results showed that when the daily intake of PACs was at least 36 mg, the risk of UTIs was reduced by 18% (RR = 0.82, 95% CI = 0.69–0.98, p = 0.03).
A randomized placebo-controlled study in 72 patients with recurrent UTI examined PAC-A supplementation for 12 weeks: the overall efficacy and tolerability of standardized cranberry extract containing PAC-A as a food supplement were superior to placebo in terms of reduced bacterial adhesion, bacterial MRHA negativity, urine pH reduction, and in preventing recurrent UTI (dysuria, bacteriuria, and pyuria). Larger randomized controlled trials are needed to elucidate the precise role, exact dose, and optimal duration of PAC-A therapy in patients at risk of recurrent UTI.
A Cochrane systematic review framework (the review first published in 1998 with subsequent updates) has assessed the totality of cranberry UTI evidence. A Cochrane systematic review published in 2012 could not definitively conclude on the efficacy of cranberry products for the prevention of recurrent UTI mainly because of a lack of observance (i.e., compliance issues with some preparations). There is still conflicting scientific data about the usefulness of cranberry products in preventing UTIs, with variability partly attributed to inconsistent PAC content and measurement methods across products. Evidence characterization: moderate, specifically for A-type PAC-standardized extracts at ≥36 mg/day in women susceptible to recurrent UTI; weaker for other preparations or populations.
Oral ingestion of Pycnogenol® has been shown to protect against skin damage induced by UV irradiation, modulate skin pigmentation, and enhance skin barrier function and extracellular matrix homeostasis. Pycnogenol® has moisturizing properties and improves the elasticity of human skin by increasing hyaluronic acid and collagen type I.
A randomized trial assessed oral French maritime pine bark extract (Flavangenol®) in photoaged skin: to evaluate the clinical efficacy of French maritime pine bark extract (PBE) in the improvement of photodamaged facial skin, researchers conducted a randomized trial of oral supplementation with PBE. One hundred and twelve women with mild to moderate photoaging of the skin were randomized to either a 12-week open trial regimen of 100 mg PBE supplementation once daily or to a parallel-group trial regimen of 40 mg PBE supplementation once daily. Both regimens demonstrated improvements in measures of photoaging.
Protection against UV-radiation-induced erythema was found in a clinical study following oral intake of Pycnogenol®. Across 39 RCTs including 2,009 subjects, Pycnogenol® supplementation has been shown to beneficially affect skin health, including parameters such as hydration, elasticity, and pigmentation. Evidence characterization: moderate; several small-to-medium RCTs with consistent direction, primarily for Pycnogenol®-branded extract; generalizability to all proanthocyanidin preparations uncertain.
Among the 39 randomized, double-blind, placebo-controlled human clinical trials on Pycnogenol®, cognition was one of the beneficially affected areas. The anti-inflammatory and antioxidant properties of Pycnogenol® have been investigated further, contributing to increased research on its effects on human health, such as cognitive function, among others. Evidence characterization: preliminary; positive signals in RCTs with Pycnogenol®, but this is a single standardized product, and evidence for proanthocyanidins from other sources in cognitive outcomes is much more limited.
Procyanidins possess antioxidant, antibacterial, anti-inflammatory, and antineoplastic activity, and have the capacity to address diverse oral diseases including oral cancer, periodontitis, dental caries, diseases of the oral mucosa, endodontic root canal issues, peri-implantitis, and dental restoration.
Regarding dental caries specifically: proanthocyanidins can effectively inhibit caries through (1) reducing caries-causing pathogens such as Streptococcus mutans and their biofilms; and (2) promoting the mineralization of hydroxyapatite. Most evidence in oral health comes from in vitro and animal models rather than clinical trials. Evidence characterization: largely preclinical (in vitro, animal); clinical evidence in humans is sparse and represents an active but early research area.
The modes of action of proanthocyanidins in cancer were evaluated through a number of in vitro and in vivo studies which showed their potential role as anti-carcinogenic agents. Extracts from grape peels, grape seeds, and black raspberries — sources that contain high concentrations of PAC — have demonstrated selective suppression of tumorigenic phenotypes in oral cancers, specifically in oral squamous cell carcinomas. PAC derived from grape seed, green tea, and lowbush blueberry exhibited broad anti-proliferative properties against multiple cell lines, including colon, prostate, breast, and oral cancers.
Evidence characterization: predominantly preclinical (cell lines and animal models); there are no completed large-scale phase III clinical trials establishing proanthocyanidins as effective cancer treatments or chemoprevention agents in humans. Results from in vitro and in vivo studies are promising but not transferable to clinical recommendations.
Animal studies demonstrate that proanthocyanidins reduce the plasma levels of atherogenic apolipoprotein B-triglyceride-rich lipoproteins and LDL-cholesterol but increase antiatherogenic HDL-cholesterol. In humans, the picture is more complex. Ingestion of procyanidins has been reported to significantly reduce weight gain, decrease adipose tissue mass, and ameliorate insulin tolerance in various animal models and human studies. Some studies suggest that the consumption of procyanidin-rich foods affects the expression of key genes involved in the regulation of anti-oxidative enzymes and of glucose and lipid metabolism. Evidence characterization: promising in animal models; mixed and preliminary in human clinical trials.
In asthma patients, symptom scores and circulating leukotrienes are reduced and lung function is improved following administration of Pycnogenol® in clinical studies. Evidence characterization: limited; based on a small number of trials, primarily with Pycnogenol®. Not generalizable to all proanthocyanidin sources.
Pycnogenol® relieves premenstrual symptoms, including abdominal pain, and this action may be associated with the spasmolytic action of some phenolic acids. Multiple clinical trials and cohort studies have found that proanthocyanidins contribute to the improvement of menopausal symptoms. Evidence characterization: preliminary to moderate; small RCTs demonstrate positive signals for specific OPC extracts.
Dosages vary considerably by indication and preparation. The following are dosages as reported in identified studies and should be understood in that context:
Based on available evidence across human and experimental studies, proanthocyanidins have been associated with the following body systems:
Clinical trials and cohort studies have found that proanthocyanidins contribute to the prevention of cardiovascular disease, hypertension, obesity, cancer, osteoporosis, and urinary tract infection, as well as the improvement of menopausal symptoms, renal function, and skin damage.
Grape seed extract (GSE) was examined for acute and subchronic oral toxicity using Fischer 344 rats and for mutagenic potential by the reverse mutation test, the chromosomal aberration test, and the micronucleus test. No evidence of acute oral toxicity at dosages of 2 and 4 g/kg, and no evidence of mutagenicity in these tests was found. Administration of GSE as a dietary admixture at levels of 0.02, 0.2, and 2% (w/w) to rats for 90 days did not induce noticeable signs of toxicity.
The no-observed-adverse-effect level (NOAEL) of GSE in the subchronic toxicity study was 2% in the diet (equal to 1,410 mg/kg body weight/day in males and 1,501 mg/kg body weight/day in females). The results indicated a lack of toxicity and support the use of proanthocyanidin-rich extract from grape seeds for various foods.
The LD₅₀ value of the grape seed proanthocyanidin extract was found to be greater than 4 g/kg in male and female rats combined in the oral acute toxicity study. Bombardelli and Morazzoni reported that the acute oral LD₅₀ value of proanthocyanidin oligomers was approximately 4 g/kg.
Review of several clinical trials that investigated Pycnogenol® indicated that tolerance of the supplement was very good with only rare side effects, most referring to gastric discomfort. Similar observations were reported for enzogenol, a combination of an extract of Pinus radiata bark and vitamin C.
Proanthocyanidin violates Lipinski's Rule of Five (three violations) due to its high molecular weight, excessive hydrogen bond donors, and acceptors, which may limit its oral bioavailability and drug-likeness. While proanthocyanidin demonstrates promising safety and absorption characteristics, its poor permeability and physicochemical violations warrant optimization or alternative delivery strategies to enhance its systemic availability and clinical applicability.
Computational assessment suggests a minimal risk of drug–drug interactions mediated by CYP3A4, a major metabolizing enzyme. However, other interaction signals have been identified:
Large double-blind clinical studies need to be conducted on proanthocyanidins to provide more information on their clinical efficacy and safety so that clinical implications of proanthocyanidins can be suggested as therapeutic remedies supported by sufficient scientific evidence. Data on safety in pregnancy, lactation, pediatric populations, and severe renal or hepatic impairment remain limited.
Although proanthocyanidins exert several types of bioactivities, such as antioxidant, antimicrobial, cardioprotective, and neuroprotective activity, their exact mechanisms remain unclear. Due to the complexity of the structure of proanthocyanidins, including their various monomers, different linkages, and isomers, investigation of their bioavailability and metabolism is limited, which further hinders the explanation of their bioactivities.
More studies about the safety and the effectiveness of different constituents of proanthocyanidins are needed. Large-sample clinical trials are required. Key limitations in the existing evidence base include: heterogeneity in the type, source, and degree of standardization of proanthocyanidin preparations used across trials; inconsistent dosing; poor characterization of bioavailable metabolites; short follow-up durations; and reliance on surrogate endpoints rather than hard clinical outcomes.
Condiciones de salud que proantocianidinas puede ayudar a apoyar.
Proanthocyanidins (condensed tannins from grape seed, pine bark, and berries) improve endothelial function, inhibit ACE, reduce LDL oxidation, and lower blood pressure. Meta-analyses of grape seed extract RCTs show SBP reduction of ~6 mmHg. Life Extension's cardiovascular protocol listed proanthocyanidins from grape seeds and pine bark among anti-atherogenic compounds improving endothelial function.
Proanthocyanidins (PACs, condensed tannins) are among the most potent dietary antioxidants, found in grape seeds, berries, and pine bark. Clinical trials with grape seed and pine bark (Pycnogenol) PAC extracts demonstrate significant reductions in oxidative stress, improved vascular function, and anti-aging effects in middle-aged adults.
Proanthocyanidins (OPCs, condensed tannins) are potent inhibitors of collagenase and elastase enzymes that degrade dermal collagen and elastin, and among the most potent antioxidants protecting skin collagen from oxidative fragmentation. Clinical studies with grape seed OPC supplementation demonstrate improved skin elasticity and barrier function in adult women.
Proanthocyanidins (OPCs) from grape seed and pine bark are well-documented for chronic venous insufficiency and spider veins. They strengthen capillary walls, protect collagen, reduce vascular permeability, and have antioxidant effects. Multiple small clinical studies and a Cochrane-referenced review support their efficacy for venous insufficiency symptoms including spider veins.
Proanthocyanidins (PACs), especially A-type PACs found in cranberry, are the primary bioactive compounds responsible for the anti-adhesive mechanism underlying cranberry's UTI preventive effect. They inhibit E. coli fimbrial adhesion to uroepithelial cells. Multiple RCTs on cranberry PAC extracts have demonstrated significant reduction in recurrent UTI risk, and high-PAC doses show a dose-dependent effect in meta-analyses.
Proanthocyanidins are the class of polyphenol compounds in grape seed and pine bark principally responsible for their venous effects. They strengthen capillary walls, reduce permeability, and exert anti-inflammatory effects relevant to varicose veins and CVI. The evidence base, shared with Oligomeric proanthocyanidins and Pycnogenol, includes multiple double-blind placebo-controlled clinical studies in CVI and varicose vein patients showing significant symptomatic benefit.
Proanthocyanidins (oligomeric proanthocyanidins, OPCs) from grape seed and pine bark are proposed natural treatments for hemorrhoids based on their capillary-stabilizing and anti-inflammatory properties. EBSCO Research Starters lists oligomeric proanthocyanidins among proposed natural treatments for hemorrhoids. Evidence is primarily mechanistic and indirect via chronic venous insufficiency studies.
Sistemas corporales que proantocianidinas puede ayudar a apoyar.
Volver